Wood Gavin 4

4 · Adaptimmune Therapeutics PLC · Filed Apr 1, 2020

Form 4

Period: 2020-04-01

Chief Financial Officer

Transactions

Award
Option to purchase Ordinary Shares
2020-04-01+565,000→ 565,000 total
Exercise: $0.00Exp: 2030-04-01→ Ordinary Shares (565,000 underlying)
Award
Option to purchase Ordinary Shares
2020-04-01+2,500,000→ 2,500,000 total
Exercise: $0.45Exp: 2030-04-01→ Ordinary Shares (2,500,000 underlying)

Footnotes (4)

[F1]The exercise price was converted from GBP0.36 based on an exchange rate of U.S.$1.245481 to GBP1.00. The actual exercise price will be the pounds sterling amount.
[F2]Exercisable as to 625,000 Ordinary Shares on April 1, 2021 and will be exercisable as to the remainder in monthly installments of 52,080 Ordinary Shares on the first of each month from May 1, 2021 through March 1, 2024 and 52,200 Ordinary Shares on April 1, 2024.
[F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.245481 to GBP1.00. The actual exercise price will be the pounds sterling amount.
[F4]Exercisable as to 141,250 Ordinary Shares on April 1, 2021 and will be exercisable as to the remainder in annual installments of 141,250 Ordinary Shares on the first of each April from April 1, 2022 through April 1, 2024.

Documents

1 file